Literature DB >> 17945191

Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids.

Ulf Siemoneit1, Bettina Hofmann, Nicole Kather, Tobias Lamkemeyer, Johannes Madlung, Lutz Franke, Gisbert Schneider, Johann Jauch, Daniel Poeckel, Oliver Werz.   

Abstract

Boswellic acids (BAs) are assumed as the anti-inflammatory principles of Boswellia species. Initially, it was found that BAs inhibit leukotriene biosynthesis and 5-lipoxygenase (EC number 1.13.11.34), whereas suppression of prostaglandin formation and inhibition of cyclooxygenases (COX, EC number 1.14.99.1) has been excluded. Recently, we demonstrated that BAs also interfere with platelet-type 12-lipoxygenase. Here, we show that BAs, preferably 3-O-acetyl-11-keto-beta-BA (AKBA), concentration-dependently inhibit COX-1 product formation in intact human platelets (IC(50)=6 microM) as well as the activity of isolated COX-1 enzyme in cell-free assays (IC(50)=32 microM). The inhibitory effect of AKBA is reversible, and increased levels of arachidonic acid (AA) as substrate for COX-1 impair the efficacy. COX-1 in platelet lysates or isolated COX-1 selectively bound to an affinity matrix composed of immobilized BAs linked via glutaric acid to sepharose and this binding was reversed by ibuprofen or AA. Automated molecular docking of BAs into X-ray structures of COX-1 yielded positive Chemscore values for BAs, indicating favorable binding to the active site of the enzyme. In contrast, COX-2 was less efficiently inhibited by BAs as compared to COX-1, and pull-down experiments as well as docking studies exclude strong affinities of BAs towards COX-2. In conclusion, BAs, in particular AKBA, directly interfere with COX-1 and may mediate their anti-inflammatory actions not only by suppression of lipoxygenases, but also by inhibiting cyclooxygenases, preferentially COX-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945191     DOI: 10.1016/j.bcp.2007.09.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Triterpenoid resinous metabolites from the genus Boswellia: pharmacological activities and potential species-identifying properties.

Authors:  Yuxin Zhang; Zhangchi Ning; Cheng Lu; Siyu Zhao; Jianfen Wang; Baoqin Liu; Xuegong Xu; Yuanyan Liu
Journal:  Chem Cent J       Date:  2013-09-12       Impact factor: 4.215

2.  SZB120 Exhibits Immunomodulatory Effects by Targeting eIF2α to Suppress Th17 Cell Differentiation.

Authors:  Linjiao Chen; Jing Bai; Danhong Peng; Yuanyuan Gao; Xiaojie Cai; Junxun Zhang; Sibei Tang; Liman Niu; Yang Sun; Fangzhou Lou; Hong Zhou; Qianqian Yin; Zhikai Wang; Libo Sun; Xuemei Du; Zhenyao Xu; Hong Wang; Qun Li; Honglin Wang
Journal:  J Immunol       Date:  2021-01-22       Impact factor: 5.422

Review 3.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

4.  Metabolic Profile of 3-Acetyl-11-Keto-β-Boswellic Acid and 11-Keto-β-Boswellic Acid in Human Preparations In Vitro, Species Differences, and Bioactivity Variation.

Authors:  Yonglei Cui; Xiangge Tian; Jing Ning; Chao Wang; Zhenlong Yu; Yan Wang; Xiaokui Huo; Lingling Jin; Sa Deng; Baojing Zhang; Xiaochi Ma
Journal:  AAPS J       Date:  2016-06-21       Impact factor: 4.009

5.  Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation.

Authors:  Hongmei Cao; Rui Yu; Yongsoo Choi; Zhong-Ze Ma; Hongjie Zhang; Wei Xiang; David Yue-Wei Lee; Brian M Berman; Kamal D Moudgil; Harry H S Fong; Richard B van Breemen
Journal:  Pharmacol Res       Date:  2010-02-24       Impact factor: 7.658

Review 6.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

7.  The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.

Authors:  A Rossi; C Pergola; A Koeberle; M Hoffmann; F Dehm; P Bramanti; S Cuzzocrea; O Werz; L Sautebin
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

8.  Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.

Authors:  Sawsan A Zaitone; Bassant M Barakat; Shymaa E Bilasy; Manal S Fawzy; Eman Z Abdelaziz; Noha E Farag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-24       Impact factor: 3.000

Review 9.  Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents.

Authors:  Reen-Yen Kuo; Keduo Qian; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2009-08-13       Impact factor: 13.423

10.  The selective 5-LOX inhibitor 11-keto-β-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.

Authors:  Shimaa M Elshazly; Dalia M Abd El Motteleb; Noha N Nassar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.